It is a public statement, actionable by the SEC for misrepresentation, that the information in the paper reinforces the data developing in the trials.
Not sure on your point here. Didn't say he did anything that was actionable. He is perfectly within his right to state that 2-73 has actions that other S1Rs have when the data suggests so.
It doesn't have to be "unique", but trail results so far indicate that 2-73 is better than anything on the market.
The data developed so far is extraordinarily weak in showing it has any clinical effect at all. This is a step removed from comparing it to anything on the market. If it had a unique mechanism of action it might bolster the hope for better results somewhat but instead, in this model, it shows weaker action than other S1Rs...including those in AVXL's pipeline.
@Investor2014: Converging evidence that an established S1R agonist has S1R agonist effects is hardly a lofty or laudable goal...and especially so if those effects are relatively weak.
Market Data 
Markets 
AI
